Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We ar... more >

Stock Quotemore >
C
$1.10
0.00 (0.00%)
Bellerophon (Nasdaq: BLPH)
Data as of 09/21/17 4:00 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
09/07/17
Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
WARREN, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, and the Ladenburg Thalmann 3rd Annual Healthcare Conference. Rodman & Renshaw 19th Annual Global Investment Conference Date: Tuesday, September ... 
09/05/17
Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
Study Met its Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements in Six-Minute Walking Distance, Hemodynamics and Blood Vessel Volume WARREN, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced positive top line data from a Phase 2 clinical trial evaluating INOpulse® in patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD... 
08/07/17
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update
WARREN, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the second quarter ended June 30, 2017. “We continue to be encouraged with the progress of our Phase 3 clinical program in PAH, as well as Phase 2 programs in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and chronic obstructive pulmonary disease (PH-COPD).  In o... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources